ReviewBMC neurology2016
Albumin and multiple sclerosis.
Review in BMC neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 98 citations in OpenAlex.
- Idebenone does not inhibit disability progression in primary progressive MS.Multiple sclerosis and related disorders · 2020Trial
- Systemic inflammation in optic neuropathies: comparative insights from hematological and composite indices.BMC ophthalmology · 2026Article
- Cerebrospinal fluid/plasma albumin quotient in dementia: a systematic review of biomarker potential and clinical associations.GeroScience · 2026Review
- A novel murine model of LITT for glioblastoma reveals tumor reduction, BBB permeabilization, and drug delivery via ThermoDoxDrug delivery and translational research · 2026Article
- Association between serum non-enzymatic antioxidants and cognitive impairment in drug-naïve patients with schizophrenia.BMC psychiatry · 2026Article
- Association of the Albumin-Bilirubin score with 7-day incident delirium risk following bloodstream infection in critically ill adults: evidence from a propensity-weighted cohort.BMC infectious diseases · 2026Article
- Reexamining the Role of Amyloid β Clearance from the Brain: Exporting Labile Iron from the Interstitial Fluid Performs a Protective Function.International journal of molecular sciences · 2026Review
- Blood-brain barrier integrity and prevalence of intrathecal T helper 17.1 cells in Huntington´s disease.PloS one · 2026Article
- Physicochemical Stability and Cross-Context Validation of PEGylated Human Serum Albumin Nanoparticles for Dual Neurotrophin Delivery in the Rabbit Eye and Oxidative Stress Models.International journal of nanomedicine · 2026Article
- Disruption of the cerebrospinal fluid-plasma protein balance in cognitive impairment and aging.Nature medicine · 2025Article
- Comparative proteomic analysis of astrocytoma tissues from patients with and without seizures.Scientific reports · 2025Article
- The Importance of Bright Spotty Lesions on Magnetic Resonance Imaging in Predicting Chronic Neuropathic Pain in Myelitis.Journal of clinical medicine · 2024Article
- Blood-brain barrier disruption following brain injury: Implications for clinical practice.Histology and histopathology · 2024Review
- Tumor necrosis factor regulates leukocyte recruitment but not bacterial persistence during Staphylococcus aureus craniotomy infection.Journal of neuroinflammation · 2024Article
- Astrocytes sense glymphatic-level shear stress through the interaction of sphingosine-1-phosphate with Piezo1.iScience · 2024Article
- Biomaterial strategies for regulating the neuroinflammatory response.Materials advances · 2024Review
- Probing Protein Structural Changes in Alzheimer's Disease via Quantitative Cross-linking Mass Spectrometry.Analytical chemistry · 2024Article
- Immunological Profile and Markers of Endothelial Dysfunction in Elderly Patients with Cognitive Impairments.International journal of molecular sciences · 2024Article
- Albumin and multiple sclerosis: a prospective study from UK Biobank.Frontiers in immunology · 2024Article
- Serum Albumin Level Can Predict Immunotherapy Response of Neuromyelitis Optica Spectrum Disorders in the Acute Phase.Journal of inflammation research · 2024Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leakage of the blood-brain barrier (BBB) is a common pathological feature in multiple sclerosis (MS). Following a breach of the BBB, albumin, the most abundant protein in plasma, gains access to CNS tissue where it is exposed to an inflammatory milieu and tissue damage, e.g., demyelination. Once in the CNS, albumin can participate in protective mechanisms. For example, due to its high concentration and molecular properties, albumin becomes a target for oxidation and nitration reactions. Furthermore, albumin binds metals and heme thereby limiting their ability to produce reactive oxygen and reactive nitrogen species. Albumin also has the potential to worsen disease. Similar to pathogenic processes that occur during epilepsy, extravasated albumin could induce the expression of proinflammatory cytokines and affect the ability of astrocytes to maintain potassium homeostasis thereby possibly making neurons more vulnerable to glutamate exicitotoxicity, which is thought to be a pathogenic mechanism in MS. The albumin quotient, albumin in cerebrospinal fluid (CSF)/albumin in serum, is used as a measure of blood-CSF barrier dysfunction in MS, but it may be inaccurate since albumin levels in the CSF can be influenced by multiple factors including: 1) albumin becomes proteolytically cleaved during disease, 2) extravasated albumin is taken up by macrophages, microglia, and astrocytes, and 3) the location of BBB damage affects the entry of extravasated albumin into ventricular CSF. A discussion of the roles that albumin performs during MS is put forth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.